Incentive Sensitivity as a Behavioral Marker of Clinical Remission From Major Depressive Episode

Thomas Mauras, MD; Marc Masson, MD; Philippe Fossati, PhD, MD; and Mathias Pessiglione, PhD

Published: June 22, 2016

Article Abstract

Background: Reduction of goal-directed behaviors is frequently observed in depression and may be linked to dysfunction of incentive motivation process.

Objective: To investigate whether incentive sensitivity could constitute a behavioral marker of clinical remission in major depression.

Methods: A handgrip force measurement device was employed to assess the impact of incentive motivation and emotional manipulation on the effort produced by remitted patients (n = 20) compared to matched depressed patients (n = 22) and healthy controls (n = 26). Depressed and remitted patients fulfilled the major depressive disorder DSM-IV criteria for current episode and remission state, respectively. The study was performed between March and July 2013.

Results: Relative to patients with acute depression, patients after remission retrieved a normal sensitivity to incentives (t1,40 = 4.18, P < 1.5 × 10−4), but relative to healthy controls, they kept an abnormally high susceptibility to emotional arousal (t1,44 = 2.4, P = .02). Normalization of incentive sensitivity exhibited in the behavioral test was associated with improvement of apathy measured on the clinical scale.

Conclusions: Using a simple behavioral paradigm at patients’ bedside, we could identify the factors influencing effort production, so as to discriminate remitted patients from both depressed patients and healthy controls.

Volume: 77

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF


Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...